Clinical Assessment of Pharmacokinetics, Efficacy, and Safety of 10% IVIg in PID Patients

Summary

The purpose of this study was to assess efficacy and safety of Kedrion Immunoglobulin 10% (KIg10) in participants with Primary Immunodeficiency (PID).

Timeline

Start

2019-04-30

Primary completion

2020-12-21

Completion

2020-12-21

Publications

• Roifman CM, McNeil D, Lumry W, Wasserman RL, Kanarek H, Moy J, Zecca T, Rehman SM, Raasch J, Lehman H, Norton M, Calcinai M, Kleyn A, Perez E; CARES10 Investigator Working Group. Clinical Evaluation of Pharmacokinetics, Efficacy, and Safety of a 10% Immunoglobulin in Primary Immunodeficiency Disease (CARES10 Study). Adv Ther. 2026 Jul;43(7):3148-3164. doi: 10.1007/s12325-026-03594-4. Epub 2026 May 9.

Drugs

Indications